HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Should Strike Cosmetics From IND Guidance – Industry Counsel

This article was originally published in The Rose Sheet

Executive Summary

By misstating elements of the U.S. Food, Drug and Cosmetic Act, FDA’s guidance on Investigational New Drug applications is in violation of the law, the Personal Care Products Council’s legal head says. FDA surprised stakeholders by including IND requirements for cosmetics in a final guidance released in late 2013, subsequently opening the section up for comments, which were due April 7.

Advertisement

Related Content

FDA Guidance Could Impose Drug-Like Burden On Cosmetic Trials
Advertisement
UsernamePublicRestriction

Register

RS018980

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel